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Accurate genome-wide detection of somatic mutations with low variant allele frequency
(VAF, <1%) has proven difﬁcult, for which generalized, scalable methods are lacking. Herein,
we describe a new computational method, called RePlow, that we developed to detect
low-VAF somatic mutations based on simple, library-level replicates for next-generation
sequencing on any platform. Through joint analysis of replicates, RePlow is able to remove
prevailing background errors in next-generation sequencing analysis, facilitating remarkable
improvement in the detection accuracy for low-VAF somatic mutations (up to ~99%
reduction in false positives). The method is validated in independent cancer panel and
brain tissue sequencing data. Our study suggests a new paradigm with which to exploit
an overwhelming abundance of sequencing data for accurate variant detection.
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Next-generation sequencing (NGS) has afforded research-ers the means with which to investigate somatic variantswith tremendous accuracy. For many years, the usefulness
of NGS was highlighted in cancer research, wherein mutations
are clonally expanded and shared by the majority of cancer
cells, thereby providing a sufﬁcient variant allele frequency (VAF)
that can be detected in a sample. However, recent applications
of genome analysis, such as in liquid biopsy1, noninvasive pre-
natal testing2, somatic mosaicism3, tumor subclones4, and
cell lineage tracing5, are fraught with somatic single-nucleotide
variants (SNVs) that exist at low VAF. Increasing evidence sup-
ports the contribution of low-level SNVs to various noncancerous
diseases6–9. Accurate detection of these SNVs may prove to be
the key to further expanding the use of NGS in biomedical
research.
Detection of low-VAF somatic mutations is a challenge in
conventional NGS. Even at a high-read depth, NGS shows a rapid
drop in detection accuracy of low-VAF somatic mutations10–12.
Attempts to address this issue have mainly focused on modifying
sequencing protocols, such as tagging unique molecular
identiﬁers13,14, generation of tandem-copies15, adding DNA-
repair enzymes16, and selection of mutation-harboring sub-
samples (e.g., single-cell sequencing17). The common aim of these
methods is to enhance signal-to-noise ratios by amplifying
mutation-driven variant alleles while discriminating erroneous
alterations in nonmutation sites: the majority of these errors are
believed to originate from external DNA damage18,19, which has
been found to pervasively confound variant identiﬁcation in
genome resequencing projects16. While technical advances that
seek to reduce these errors are important, a more general and
sustainable approach is required to accelerate practical applica-
tion of conventional NGS data.
In science, one of the key processes through which to yield
accurate and reliable data is a measurement of replicates. Unlike
other biological experiments, however, NGS for variant detection
has been granted an exemption from experimental replication,
mostly due to costs and a lack of analysis methods20. As NGS is
rapidly diminishing in cost, we suspect that the use of replication
could provide a general, efﬁcient, and widely applicable means by
which to detect rare but biologically important somatic variants.
Here, we develop a new probabilistic model (named RePlow)
that jointly analyzes library-level replicates for accurate detection
of low-VAF somatic mutations. Importantly, the method is
platform independent. Given sequencing data, RePlow infers
patterns of background errors intrinsic to a data set. According to
these inferred error proﬁles, variants are called by identifying
mismatched alleles for all replicates simultaneously. Compared to
a single-sample-based variant calling, RePlow shows marked
improvement in both sensitivity and speciﬁcity. Furthermore, we
are able to conﬁrm the accuracy of our model in independent
cancer panels and to discover low-VAF variants (~0.5%) that
were not detected with conventional variant calling settings. Our
model demonstrates that exploiting replicates can be a cost-
effective, scalable, and sustainable solution for detecting low-level
somatic mutations, which has continued to remain elusive.
Results
The current state of detecting low-VAF somatic mutations.
First, we sought to examine the bona ﬁde accuracy of current
conventional NGS techniques and algorithms in calling low-VAF
somatic mutations. We prepared a test-base data set for the
measurement (Fig. 1a). Unlike in silico simulations, directly
pooled genomic materials reﬂect the variety of errors across the
entire sequencing step. Thus, genomic DNA from two indepen-
dent blood samples was mixed to mimic somatic mutations at
four different VAFs: 0.5, 1, 5, and 10% (designated as samples
A–D, respectively). Sequencing of the material provided a set of
control positives (645 true variants) and negatives (66,485 non-
variant sites) for determining detection accuracy, including sen-
sitivity and false-positive rate (FPR). The test-base data set
consisted of library- and sequencing-level replicates for three
distinct platforms: hybridization-capture-based Illumina sequen-
cing (ILH, up to 1000×) and amplicon-based Illumina and
Ion Torrent sequencing (ILA and ITA, respectively, up to
10,000×) (see Methods). The sequencing data sets were further
downsampled by an interval of 100× (ILH) or 1000× (ILA and
ITA) to investigate the effect of read depths (Supplementary
Table 1). The feasibility of detecting low-VAF variants with eight
somatic variant callers was evaluated on the test-base data21–27.
In their near-default settings (disabled coverage limit), most
callers lost most of the variants in samples A and B since the
majority of them were not originally designed to detect such low
levels (Supplementary Fig. 1). Parameter optimizations including
tumor-cellularity (see Methods) enabled detection of the lost
variants, however, it was also accompanied by a tremendous
increase in false-positive calls (7–400 k per Mb, Fig. 1b and
Supplementary Fig. 2). While increasing the read depth generally
improved the sensitivity, it did not enhance the overall perfor-
mance of the callers due to large increases in FPRs. We noted a
remarkably higher FPR for ILA, in which targeted genomic
regions are covered by a smaller number of amplicons, compared
to ITA, thus requiring more polymerase chain reaction (PCR)
cycles for library preparation to achieve the same depth: PCR
generates DNA damage, leading to errors in sequencing. In such
an environment, high-depth sequencing can even lower sensi-
tivity (Fig. 1b left). We found that most of these false-negative
calls in high-depth ILA were triallelic, caused by the accumulation
of errors at true variant sites (Supplementary Fig. 3).
The allele frequency distributions of the true and false calls in
the test-base data set conﬁrmed the intractability of current forms
of sequencing data analysis. We found a consistent level of
background errors (1–3%) in all three platforms (higher in
amplicon sequencing) that dominated true signals at a VAF
of ≤1% (Fig. 1c). Accordingly, additional ﬁltering with a hard
VAF cut-off value was unable to separate erroneous variants.
Likewise, the distributions of probabilistic odd-ratio scores
(LODT score23) severely overlapped between mutations and
errors (Fig. 1c right). Moreover, except read-pair orientation bias
in ILH, none of the commonly used features for variant ﬁltration,
such as base call quality, mapping quality, number of per-read
mismatches, and indel proximity, or common postﬁltering steps
were able to mitigate the problem (Supplementary Figs. 4 and 5).
These results refute previous perspectives that suggest errors
can be distinguished from true low-level mutations through
stringent ﬁlters16,20.
Using replicates: primitive models. The NGS sequencing process
can be divided into three steps: (1) sample preparation, (2) library
preparation, and (3) sequencing, each of which can generate
genuine errors (Fig. 2a). For example, sample contamination,
PCR ampliﬁcation error, and overlapping ﬂuorescence signals are
frequently observed errors in each respective step20. Technical
replication aims to measure the variance of these errors between
data sets. However, said measurement is limited by the time of the
replication, because errors generated in preceding steps will be
shared in all following replicates. Thus, repeated sequencing of
the same libraries or a collection of sequencing reads does not
provide any information concerning PCR errors or DNA damage.
Accordingly, we referred to library-level replicates as proper
technical replicates in this study.
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Fig. 1 Assessment of conventional algorithms for detecting mutations with low-allele frequency. a Schematic of experimental design for test-base
sequencing data. Four distinct sample mixtures (A, B, C, and D) were prepared and sequenced with three different sequencing platforms (ILH, ILA, and
ITA). Constructed libraries from each platform were sequenced twice to produce sequencing replicates (X11 and X12). For samples A and B, two
independent sets of sequencing library were additionally prepared to sequence data from library replicates (X21 and X31). Each set of sequencing data was
sequentially downsampled ten times to evaluate the effects of read depth. All generated datasets were analyzed, and average performances were reported
for each depth and platform. b Sensitivity and FPR of conventional methods (MuTect with adjusted parameters, others in Supplementary Figs. 1 and 2) by
sequencing depth and VAF for each sequencing platform. Points are depicted within the maximum depth of the sequencing data (Supplementary Table 1).
Error bars, 95% conﬁdence intervals. Source data are provided as a Source Data ﬁle. c Distribution of allele frequencies and probabilistic odd-ratio scores
(LODT) for true-positive and false-positive calls for each sample mixture (colored by blue and red, respectively). ILH hybrid-capture-based Illumina
sequencing, ILA amplicon-based Illumina sequencing, ITA amplicon-based Ion Torrent sequencing, VAF variant allele frequency, FPR false-positive rate
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In the absence of systematic methods, two primitive
approaches can be implemented to test the effect of replication
on detecting low-VAF variants: intersection and BAM-merge
(Fig. 2b and Methods). The intersection model is based on the
reproducibility of variants. Thus, only variants that are called in
every replicate are ﬁnally reported. The intersection model can be
seen as the conventional “call-and-validate” strategy, where initial
candidate variants undergo independent validation in subsequent
data sets. In the BAM-merge model, alignment ﬁles (BAM ﬁles)
from all replicates are merged to a single ﬁle and fed into a caller.
In both models, the expected beneﬁts rely on an assumption of
error randomness: ideally, true mutation signals will accumulate,
and errors will be dispersed (Fig. 2b upper).
In the present study, we found that both models only provided
mediocre improvement above conventional single-sample-based
variant calling for the low-level mutation detection (Fig. 2c). The
intersection model substantially lowered sensitivity, as was
expected. Moreover, it failed to effectively reduce FPRs in two
amplicon-based platforms (ILA and ITA in Fig. 2c green lines,
and Supplementary Fig. 6). While the BAM-merge model
substantially increased sensitivity in two platforms (ILH and
ITA), it generated a troubling number of false positives in all
platforms (blue lines, Fig. 2c and Supplementary Fig. 6). Unlike
the ideal condition, we noted two critical factors as sources of
these inefﬁciencies (Fig. 2b lower). First, the overall amount
of background errors was higher than expected, affecting a wide
range of genomic positions. This resulted that replicates of
nonvariant sites were being called as true variants (Supplemen-
tary Fig. 7). Second, merging BAM ﬁles increased the read depth
and lowered the VAF threshold with which to achieve caller’s
probabilistic signiﬁcance, promoting false positives (Fig. 2b, lower
right). The combined effects of background errors and a higher
read depth elicited extremely complex model behavior: for
example, the FPR in the BAM-merge model for ILA starts to
decrease from 6000× coverage (Fig. 2c middle right panel), as
more than two different erroneous alleles begin to accumulate
to form a triallelic site in the false positive sites (Supplementary
Fig. 8).
We conﬁrmed that background errors cannot be separated
with mere use of replication. Additionally, the results showed
that the primitive models do not differentiate library-level
replicates from those at the sequencing level (Fig. 2c, dotted
lines), which implies the improper use of technical replicates.
Therefore, more sophisticated approaches are needed to over-
come these challenges.
Using replicates: the RePlow model. To make better use of
replication in NGS data analysis, we developed RePlow, a new
model that jointly analyzes library-level replicates to call low-VAF
somatic mutations in a data set. In an attempt to address the
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Fig. 2 Use of replicates with primitive models. a Experimental steps in
the typical NGS process. Errors can be generated at each step. Note that
background errors in the library preparation step (red marks and bases)
cannot be discriminated with the sequencing replicates (pseudo-
replicates). b Description of primitive approaches (intersection and BAM-
merge) with their expected (upper) and real (lower) effects. Each square
represents an observed B allele for a given position. Positions with a
number of B alleles beyond the detection threshold (red dashed line) are
called as mutation candidates (positions with black squares). Both
approaches are expected to discriminate true variants (orange-shaded
positions) from false calls based on the randomness of error (upper).
However, in real high-depth data, both approaches are ineffective due to
excessive background errors (lower). c Sensitivity and FPR of the primitive
approaches with sample B (1% VAF) for each platform. Primitive
approaches were applied for both library (solid lines) and sequencing
(dotted lines) duplicates. Calls from the single sample (dashed lines) are
also depicted to evaluate the improvement with replicates. All mutation
calls were made by MuTect. Source data are provided as a Source Data ﬁle
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challenges stated above, our primary goal for the method was to
achieve robust discrimination of background errors based on
repeated observations. To achieve the goal, we designed the
model to infer a probability distribution of background errors in
each replicate, relying on the given raw data (“on-the-ﬂy man-
ner”), so as not to lose generality. Final variant calling is con-
ducted according to merged probabilities among replicates,
reﬂecting the concordance of mismatched allele compositions.
For the on-the-ﬂy error proﬁling, we devised a strategy that
measures the amount of mismatched alleles in alignment caused
by background errors, the mismatch overrepresentation score
(MOS, see Methods). In conventional models, the cause of
mismatches is regarded as either (1) the presence of variants or
(2) sequencing errors in uniquely mapped regions. The expected
amount of sequencing errors can be calculated from the collection
of base-call quality scores in mapped reads. Thereby, an
unexpectedly large number of mismatches (e.g., high VAF in
high-quality reads) is directly interpreted as the presence of true
variants. In designing RePlow, we considered background errors
as additional causes for mismatches that distort the distribution
of mismatches but are not recognized by the base-call quality.
Brieﬂy, MOS scores are calculated by the discrepancy between the
expected and the observed amount of mismatches to construct
the probability distribution functions (PDFs) of a background
error-induced VAF. We presumed that sampling MOS scores in a
large number of nonvariant sites (e.g., >10,000 base pairs) with
high-quality alignment scores could proﬁle sample-speciﬁc back-
ground errors (see Methods).
Calculation of MOS scores on a matched control sample
(variant-free) in the test-base data set identiﬁed patterns and the
levels of background errors generated for the three platforms,
each of which showed a genuine signature (Fig. 3a). The overall
error levels were higher for the amplicon-based platforms (ILA
and ITA) than the hybrid-capture platform (ILH). Additionally,
the error levels were speciﬁc to the sequence context. We
noted excessive background errors in A > G (T > C) and C > T
(G > A) transitions for ILA, which is considered a signature
of PCR error during library ampliﬁcation28. Meanwhile, ILH
data contained a higher level of C > A (G > T) substitutions,
a well-known artifact caused by DNA oxidation during the
hybrid-capture speciﬁc sonication process19. The inferred
context-speciﬁc background error proﬁles were also consistent
with the biased patterns of observed VAFs at nonmutant sites
in the test-base data set (Fig. 3b, red dots), which supports that
the major source of erroneous variant calling comes from
intractable background errors, not controllable base-call errors
(e.g., by removing low-quality reads). Using the distribution of
MOS scores from every sampled position, we attempted to
construct PDFs for two random variables: (i) VAFs acquired as
background errors and (ii) the sequence context (Fig. 3c). Since
no canonical probability distribution is known for NGS back-
ground errors, we drew the empirical cumulative distributions for
each substitution type and ﬁt them to an exponential distribution
(see Methods). In doing so, we conﬁrmed that the inferred
distributions (red lines) closely approximated their true distribu-
tions (black lines).
The VAF distribution of the test-base samples (Fig. 3b)
provided two important justiﬁcations for using replicates: (1) true
and false mutations become more separable in a higher
dimension (in contrast to a single data set, Fig. 1c), and (2)
VAFs of true variants are more concordant in replicates
(Kolmogorov–Smirnov (KS) test, P < 2.2 × 10−16, P= 9.2 × 10
−13, P= 6.7 × 10−9 for ILH, ILA, and ITA, respectively,
Supplementary Fig. 9). RePlow implements a probabilistic model
with which to quantify these two features, based on a general
number of replicates (Fig. 3d). Brieﬂy, RePlow calculates the
probabilities of being a true variant and an error for a given
position in every replicate. The probability of error is estimated
by the inferred sample-speciﬁc PDF, while the probability of
variant is estimated by binomial approximation with the averaged
VAFs, that evaluates the concordance between replicates, to give
more advantages to the candidates with concordant VAFs (see
Methods). Both probabilities are jointly analyzed to estimate the
likelihood of a true variant in a sequence context (Fig. 3d). Sites
that have a higher probability being a variant than an error are
then treated with postﬁlters to eliminate systematic errors that are
not captured by the error model (Supplementary Methods).
Passing sites are ﬁnally considered as variant candidates.
Variant detection with RePlow. We tested RePlow on the test-
base data to compare its performance with single and the pri-
mitive replication models (Figs. 4a, 1% VAF is shown). Note that
a common RePlow model was applied to the three different
platforms (ILH, ILA, and ITA) without any platform-speciﬁc
adjustments. The most prominent improvement achieved with
RePlow was a remarkable drop in FPRs (298.1, 6069.6, and 329.8
Mb−1 for ILH, ILA, and ITA, respectively, red lines in Fig. 4a),
reductions of 70.2, 97.5, and 94.4% compared to the most precise
primitive model (intersection, green lines) and reductions of 96.2,
98.4, and 96.9% compared to the single-sample calling. Moreover,
the reductions in FPR were achieved without a loss of sensitivity,
comparable to that with union or BAM-merge modeling (orange
and blue lines). These overall improvements led to outstanding
performance for RePlow in a balanced measure (F-score). Simi-
larly, RePlow achieved the highest performance at a lower VAF
(sample A, 0.5%) and with the same total sequencing throughput
(half-coverage for replicates compared to the single library) for a
minimum read depth of > 400× per replicate (Supplementary
Figs. 10 and 11). Application to triplicates increased the model
accuracy even more, especially in terms of sensitivity, although
there was a decrease in precision for ILA (Supplementary Figs. 12
and 13).
Cross-platform replication is a widely used validation method
(e.g., initial calling in ILH and validation in ILA). Being platform
independent, RePlow can be applied to any combination of
replicates generated by multiple platforms. Accordingly, we
sought to test the bona ﬁde effects of such validation scenarios
of the three platforms in pairs and in comparison to RePlow
(Fig. 4b). Although high-precision supports the reliability of
cross-platform validated variants, a signiﬁcant loss of true low-
VAF mutations was observed (sensitivities of 47.1, 57.8, and
49.3% for ILH × ILA, ILH × ITA, and ILA × ITA pairs, respec-
tively). Meanwhile, we found that joint analysis of replicates using
RePlow was superior to the cross-platform validation approach,
increasing sensitivities by more than 20% (75.8, 78.5, and 68.0%
in the same order of pairs) while maintaining high precision
(Fig. 4b, red vs. green bars). These results indicated that many
low-level mutations are falsely rejected by the current validation
method, a substantial portion of which can be rescued by RePlow.
Next, we applied RePlow to an independent dataset. A
commercial reference standard with 35 cancer hotspot SNVs
with VAFs of 1.0–1.3% was prepared and sequenced using two
widely used cancer panels (Illumina SureSelect and Ion
AmpliSeq-based, see Methods for details) in up to triplicates
(Fig. 4c and Supplementary Table 2). We found that both the
single and the primitive replication models failed to detect ~10
true mutations, especially those at triallelic sites, most of which
were successfully called by RePlow. The FPRs of the conventional
models varied across platforms, from 600 to 60,000Mb−1 (higher
in Ion AmpliSeq). However, RePlow showed reduced FPRs of
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180–250Mb−1, including a 99.24% reduction in FPR for Ion
AmpliSeq. These results conﬁrmed the general applicability of
RePlow. As false positivity in clinical multigene tests is as
devastating as false negativity, library-level replication can be
considered as an efﬁcient approach, providing a drastic gain in
speciﬁcity with only a relatively small increase in cost.
Finally, we applied RePlow to real disease data, attempting to
identify disease-associated or -causing somatic mutations with
low-allelic frequency that might have been missed in a singleton
of deep sequencing. Recently, childhood intractable epilepsy with
focal cortical dysplasia or low-grade tumor (e.g., ganglioglioma)
has been reported as being caused by low-level somatic mutations
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in MTOR or BRAF3,29,30. Importantly, a somatic mutational
burden of even ~1% in the focal brain has been deemed sufﬁcient
to cause intractable epilepsy3,31. We obtained specimens from
two intractable epilepsy patients with matched brain-peripheral
(e.g., blood or saliva) tissue found to be negative for any
pathogenic mutations in a singleton of deep targeted sequencing
of MTOR, BRAF, and other related genes. We performed two
additional replications in brain tissues from these mutation-
negative patients. In result, a total of seven mutation candidates
were called by RePlow, compared to only one candidate called
by the intersection method that did not overlap at all. Among
the seven candidates called by RePlow, novel missense mutations
in MTOR (p.S2215F) and BRAF (p.V600E) from each sample
were previously reported as disease-associated or -causing
mutations3,29,32–35. All seven mutations were tested with droplet
digital PCR; ﬁve candidates including both missense mutations
were successfully validated (Fig. 4d and Supplementary Fig. 14)
and designing primers for the remaining two candidates failed.
The two missense mutations showed extremely low VAFs in
sequencing data (0.77 and 0.45% on average), which were not able
to achieve high enough signiﬁcance levels to be detected by
previous methods. Taken together, these results support the use
of our RePlow model allow for more accurate detection of low-
level somatic mutations with far less number of false positives via
replication of conventional NGS.
Discussion
Rapid advances in DNA sequencing technology have helped
reduce the costs of sequencing at a rate that outpaces Moore’s
law. For the last 10 years, sequencing costs have declined by a
factor of ~10,000, a trend that is expected to continue. Every 1
year, researchers can generate sequencing data at a 1.5–4 times
higher throughput at the same cost. Overall, the general con-
sensus is that the cost of sequencing itself will no longer act as a
bottleneck to genome research in the near future36. Nevertheless,
merely increasing the numbers of a sample is not an ultimate
solution to attaining research objectives, such as discovery of
cancer driver mutations, which is already approaching a pla-
teau37. At this point, we need to scrutinize the directions to which
lower costs for DNA sequencing provide actual research beneﬁts
beyond sample size or read depth. We suggest that replication will
prove useful to traversing the current limits of variant detection,
facilitating robust identiﬁcation of low-level somatic mutations.
We would like to note that the use of replication is not sub-
stitutive for or mutually exclusive with other technologies for
detecting low-level somatic mutations. What we have described in
this study is not merely a speciﬁc method, moreso a paradigm for
adding a new dimension to the current methods of mutation
calling by which previously unquantiﬁable background errors in
presequencing steps can be proﬁled and undergo technical
replication. As we have shown, RePlow can be applied to multiple
platforms of completely different data characteristics without the
need for a priori background error proﬁles. By virtue of its
platform independence, RePlow should maintain the ability to
improve the performance of mutation calling for upcoming
sequencing technologies through replication. Moreover, the pos-
sibility remains for wider application to nonconventional
sequencing (e.g., single-cell sequencing and barcoded sequencing)
or to biological replicates (multiple samples from the same
individual, e.g., different tumor biopsy portions) for detecting
shared mutations with very low-allelic fractions, which would be
helpful in detecting a second-hit mutations in tumors or to
analyze the lineage and clonality. Such advances will provide us
more rigorous and extensive testing of the inﬂuence of low-level
mutations.
Methods
Construction of a spike-in, test-base genome. Spike-in, test-base data were
prepared by mixing genomic DNA from two independent blood samples. Subsets
of unique germline single-nucleotide polymorphisms (SNPs) from one sample
(reference alleles in another) served as an answer set of somatic mutations that
have been found by variant callers. We ﬁrst generated whole exome sequencing
data (WES, ~400× coverage) of each sample to verify their genotypes and to select
unique variants. Since we focused on measuring the accuracy of mutation callers
according to changes in VAF, we only considered genomic regions with high-
mapping quality (average mapping quality ≥ 58 assessed by WES data of 1000
Genomes Project) to minimize the inﬂuence of mapping ambiguity for variant
calling. We also restricted target regions to satisfy all following conditions for both
samples to avoid the inﬂuence of other biases: (i) exons containing unique variants
with a read depth ≥ 20, (ii) indel-free exons, and (iii) exons containing clipped
reads < 5. From those regions, only exons with unique heterozygous SNPs were
selected to control the overall consistency of VAFs. A total of 645 unique variants
from 564 exons were selected as an answer set for the spike-in data. To mimic
mutations with different allele frequencies, four distinct mixtures were made by
diluting samples at ratios of 0.01, 0.02, 0.1, and 0.2 to represent mutations with
VAFs of 0.5, 1, 5, and 10%. The samples were named A–D, respectively (Fig. 1a).
Intact blood gDNA from wild type sample served as a matched control. All human
tissues including blood samples for test-base data and brain tissues of intractable
epilepsy patients were obtained with informed consent in accordance with pro-
tocols approved by the Severance Hospital and KAIST Institutional Review Board
and Committee on Human Research.
Sequencing of test-base genome. Two different sequencing platforms, Illumina
and Ion Torrent, were used to generate sequencing data for all mixture samples.
For the Illumina platform, both hybridization-capture and amplicon-based
sequencing were performed to compare the results of each library preparation
method. As a result, all mixture data were sequenced through three different
platforms: ILH, ILA, and ITA. Agilent Sure Design online tools (https://earray.
chem.agilent.com/suredesign/), Illumina design studio (https://designstudio.
illumina.com), and Ion AmpliSeq Designer (https://ampliseq.com/) were used to
design custom probes that cover selected mutations for each sequencing platform.
Since the target coverage of the designed probes differed for each platform,
Fig. 3 Development of the RePlow model. a The estimated proportion of background errors (BEs) from total mismatches by substitution type. MOS values
were measured for each substitution type from total mismatches of matched control samples. Positions with germline variants were excluded to assume
that all mismatches originated from either sequencing or background errors. The ratio of the sum of MOS scores to the total mismatch count is regarded as
an estimate of the BE proportion. b VAF distribution of called mutation candidates from library replicates of sample B (1% VAF) for each platform. All
candidates were called by MuTect in at least one replicate. True positive and false-positive calls are colored in blue and red, respectively. c Empirical and
ﬁtted cumulative distribution for the VAFs of background errors. To estimate the PDF of background errors, VAF proﬁles based on the MOS value of each
position (empirical cumulative distribution, black lines) were constructed and ﬁtted by cumulative exponential distribution (red lines) (see Methods). PDFs
were then constructed for each substitution type with the estimated parameter of the cumulative exponential model. d Overview and examples of mutation
detection by RePlow. Mapped sequencing data of replicates and matched control are taken as input. For each data set, VAF proﬁles of background errors
per substitution type are constructed ﬁrst to estimate the PDF. Then, each genomic position is analyzed to calculate probabilities of being a variant or an
error using estimated concordance models with the average VAF (normal distribution) and background error proﬁles (exponential distribution),
respectively (see Methods). Both probabilities are jointly analyzed to estimate the likelihood thereof in a sequence context. Sites with a C > A mutation
(green-shaded area) show a higher VAF than A > G mutation sites (red-shaded area). However, due to the excessive occurrence of context-speciﬁc error
(C > A) and VAF discordance between replicates, RePlow selects only the A > G mutation site as a ﬁnal candidate based on the joint analysis result. MOS
mismatch over-representation score, PDF probability density function
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platform-speciﬁc answer sets were made that contained 513, 540, and 591 variants
for ILH, ILA, and ITA, respectively. For ILH, samples were processed with target
capture and library preparation according to Agilent’s protocol and sequenced on
an Illumina HiSeq 2000 sequencer (101 × 2 bp read length, ~1000× coverage).
Samples with ILA followed the TruSeq preparation protocol and were sequenced
on an Illumina HiSeq 2500 sequencer (151 × 2 bp read length, ~10,000× coverage).
Ion Ampliseq protocol was carried out for ITA with an Ion Proton sequencer
(125–275 bp amplicon range, ~10,000× coverage). All samples were sequenced
twice from each constructed library; we called these data pairs as sequencing
replicates (X11 and X12). For samples A and B (0.5 and 1% VAF), two library
replications (independent preparation of sequencing library from the same DNA
sample, X21 and X31) were additionally performed for all sequencing platforms to
compare differences in sequencing and library replication. All generated data were
downsampled 10 times (100× to 1000× for ILH and 1000× to 10,000× for ILA and
ITA) to track the detecting accuracy by sequencing depth. Details on the
sequencing data and preprocessing procedures are described in Supplementary
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Table 1 and Supplementary Methods. Information for designed target regions
per sequencing platform and platform-speciﬁc answer sets are listed in Supple-
mentary Datas 1 and 2.
Performance assessment of conventional algorithms. We attempted to measure
the conventional performance of variant calling, especially for variants with low
frequency (≤1%). All generated data were analyzed by eight variant callers:
MuTect23, VarScan221, Strelka22, VarDict24, FreeBayes, Virmid25, LoFreq26, and
deepSNV27. Default parameter settings were tested ﬁrst for each method with
minimal adjustments that disable the coverage limit. Since most algorithms were
not carefully designed for high-depth and amplicon-based sequencing data, calls
with default parameters lost most true mutations with low frequency for all plat-
forms (Supplementary Fig. 1). Thus, we adjusted parameters to recover those
variant calls. Besides each caller-speciﬁc options, three criteria were commonly
applied: (1) the exact value of expected VAF (0.5, 1, 5, and 10% for sample A–D,
respectively) was provided if a caller accepts this information. (2) If it is applicable,
minimum VAF to be called was set to 0.25% (a half of true VAF from sample A) to
remove low-level background errors without affecting true mutation detection
from sample A. (3) For amplicon datasets, ﬁlters for strand bias and clustered
positions were disabled due to the nature of their generation. Through these
adjustments, mutations at all mixture levels were successfully discovered by most
callers but could not avoid the dramatic increase of false positive rate (Supple-
mentary Fig. 2). Detailed information for parameter adjustment is described
in Supplementary Methods.
RePlow model for variant detection. Like other conventional callers, RePlow
basically detects somatic variants by comparing the probability of two alternative
models: a variant model (Mv) and a reference model (M0) that treats all mis-
matches as error calls. The major difference in RePlow is that replicated data are
considered simultaneously for the calculation of probabilities. For a genomic
position i with k replicates, we denote the total number of reads (sequencing depth)
of replicate j as nij and the number of reads with variant alleles as bij. VAFs of the
ith position from replicate j, xij, can be calculated as bij/nij. Given observations from
position i, the log ratio (Si) of probability for both models is deﬁned as:
Si ¼ log
Qk
j¼1
P Mv x
i
j
 
Qk
j¼1
P M0 x
i
j
 
0BBB@
1CCCA ¼ log
Qk
j¼1
P Mvð ÞP xij Mvj
 
Qk
j¼1
P M0ð ÞP xij M0j
 
0BBB@
1CCCA: ð1Þ
We assume that all replicates share the identical set of true mutations. Based on
this assumption, if the ith position of one replicate is assumed to be mutated, the
rest should also be mutated thus their prior probabilities will be 1. Therefore, prior
probability will be applied once, regardless of the number of replicates, and Eq. (1)
can be rewritten as follows:
Si ¼ log
P Mvð Þ
Qk
j¼1
P xij Mvj
 
P M0ð Þ
Qk
j¼1
P xij M0j
 
0BBB@
1CCCA: ð2Þ
Since P(Mv) and P(M0) are prior probabilities of being mutated or not for a
given position, summation of those values should be 1. If we can estimate each
value of Si—P(Mv), P(xij|Mv), P(M0), and P(xij|M0)—for all genomic sites, variant
candidates can be determined by selecting genomic positions with Si > 0. In other
words, observed positions that are more likely to be explained by somatic variants
than error calls will be selected as variant candidates. To achieve this, we carefully
designed both probability models Mv and M0 with unique features that have not
been considered by conventional callers.
Error model (M0) estimation. The reference model M0 supposes that all mis-
matches at a given position are generated by errors. Previous methods have gen-
erally used the base quality score of an observed mismatch to estimate the
probability that the mismatch represents an error. However, we argue that such an
approach is insufﬁcient to accurately determine this probability, depending on the
type of error involved. We found that in addition to sequencing errors, a second
type of error exists in those mismatches, which we refer to as background errors,
the two generally occurring at different experimental steps: the former at the
sequencing step and the latter at the library preparation step (Fig. 2a). Since
mismatches caused by background error do not affect their base call quality, most
previous callers continue to generate false-positive calls at positions with back-
ground errors, all of which have high base quality scores. Thus, we designed a new
model to enable estimation of the probability that mismatches remaining after
accounting for sequencing errors are background errors. We ﬁrst constructed the
adjusted VAF proﬁles that represent background errors only; we did this by sub-
tracting the portion that can be explained by sequencing errors from all mis-
matches, which portion had previously been determined using base call quality
scores. We then ﬁt a parametric distribution to utilize corresponding PDFs to
calculate the probability of being background errors.
To construct adjusted VAF proﬁles of background errors, we ﬁrst collected all
genomic positions that possess at least one nonreference alleles and estimated the
expected count of background errors for each site. Positions that were called by
GATK or commonly called by MuTect for all replicates were excluded, since there
is a high probability of them being actual germline or somatic variants. By
deﬁnition, the expected count of a sequencing error can be inferred from the base
quality scores of variant alleles. Denoting the base quality score (Phred-scale) of
read l at the genomic position i by qil, the expected count of sequencing errors for
replicate j, bSEij, can be calculated as
Pbij
l¼1 10
q
i
l
10. Then, we estimated the expected
count of background error bBEij by subtracting bSEij from the number of reads with
the variant allele bij based on our assumption, which is that a given mismatch from
a nonvariant site should either be from a sequencing or background error. We
deﬁned this discrepancy as the MOS, which represents an unexplained number of
mismatches by base-call quality (sequencing error).
MOSij ¼ bBE ij ¼ bij  bSE ij ¼ bij 
Xbij
l¼1 10
q
i
l
10: ð3Þ
We utilized the number of positions with bBEij > 0 as an empirical estimate of
the number of positions that possesses mismatches caused by background errors.
The ratio of positions with bBEij > 0 over the whole target region, fBE, is thus
considered as the estimated probability that a given position has a background
error. The value of fBE is calculated from each replicate ﬁrst and then averaged over
replicates. The only parameter that has to be supplied by the user for the RePlow
model is the probability that a given position has a somatic variant, fv. The default
value is provided as 3 × 10−6, which is a typical mutation frequency commonly
used in previous methods23. Since P(Mv) and P(M0) in the variant detection model
represent prior probabilities that a given mismatch-containing site is a mutation or
an error, the relative ratio of fv and fBE are used as P(Mv) and P(M0) for Si
calculation.
P Mvð Þ ¼ ϕv ¼
fv
fv þ fBE
; P M0ð Þ ¼ ϕBE ¼
fBE
fv þ fBE
; ϕv þ ϕBE ¼ 1: ð4Þ
For every site with bBEij > 0, the adjusted VAF xBEij is then calculated as bBEij/nij
and is used to ﬁt the distribution function. Exponential distribution is chosen to be
ﬁt, based on the observed shape of the empirical cumulative distribution function.
Maximum-likelihood estimation for the parameter of exponential distribution λBE
Fig. 4 Comparative performances of RePlow and the primitive approaches. a Performance assessment with the library replicates of test-base data. FPR,
precision, sensitivity, and F-score were measured for sample B (1% VAF). All three combinations of duplicates were tested, and their average performances
were reported with 95% conﬁdence intervals (typically smaller than marks). b Performance assessment with the combination of replicates in
multiplatforms. All pairs of library replicates between different platforms were tested with test-base data of sample B. Only the data sets with the highest
depth of each platform were used for the combination (1000× for ILH and 10,000× for ILA and ITA). Error bars, 95% conﬁdence intervals. c Independent
assessment with a reference material sequenced by two widely-used cancer panels. Detection of 35 true cancer hotspot SNVs (1–1.3% VAF) were tested
for all combinations of library triplicates (X1X2, X2X3, X1X3, and X1X2X3 are denoted as 1, 2, 3, and T, respectively). Green shading means a correct detection,
and other colors represent the reason for the rejection or no detection (with X marks). FPRs of RePlow are highlighted in orange to emphasize their
reductions therein, compared to other primitive approaches. d Experimental validation of rescued low-level mutations from the samples negative for
pathogenic mutations in previous analysis. Observed allele counts are described in each replicate (left). Droplet digital PCR results for no DNA template
(No template), DNA from healthy controls (negative), and disease samples are shown together for each site (right). Green and blue dots represent wild
type- and mutant-speciﬁc signals, respectively. Source data for a, b are provided as a Source Data ﬁle
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is computed by the ﬁtdistr package in R. Based on the estimated parameter, the
likelihood of a given observation for the M0 model can be calculated as:
P xBE
i
j M0j
 
¼ Exp xBE ij ; λBE
 
: ð5Þ
Note that estimated parameter λBE has different values for each substitution
type in a single-data set: depending on the sequencing platform, distributions of
background errors differ greatly between substitution types (Fig. 3b). Therefore,
RePlow separately performs error model estimation for each of the six substitution
types (A > C, A > G, A > T, C > A, C > G, C > T) and uses the corresponding value
of λBE for a given observation.
Variant model (Mv) estimation. The likelihood of Mv is estimated using a
binomial distribution. Since we assume that all replicates hold the same somatic
variants, concordant VAFs are expected to be observed at the mutated site. On the
other hand, errors would hardly show identical VAFs between replicates. We
devised a model to reﬂect this VAF concordance to discriminate true variants from
error calls. This model enables us to detect true mutations with the VAF less than
those of background errors (Fig. 3d). The mean value of xBEij for all replicates is
used for the success probability of a binomial trial, giving a high probability only if
concordant VAFs are observed between replicates.
bμiBE ¼Xk
j¼1
xBE
i
j
k
: ð6Þ
For each observation, nij and bBEij are considered as the number of trials and the
number of successes, respectively. Therefore, the probability of each observation
can be calculated by a binomial distribution with the estimated success probability.
P bBE
i
j Mvj
 
¼ B bBE ij; nij;bμiBE : ð7Þ
Since bBEij can be a noninteger value, the likelihood is estimated through
normal approximation of a binomial distribution
ðBðnij;bμiBEÞ  NðnijbμiBE; nijbμiBEð1 bμiBEÞÞÞ. Then, the observed VAF xBEij will also
follow a normal distribution, which is weighted by 1/nij from the approximated
distribution for bBEij:
xBE
i
j  N bμiBE;bμiBE 1 bμiBE nij
 !
: ð8Þ
Hence, the likelihood of a given VAF observation from the Mv model can be
calculated as:
P xBE
i
j Mvj
 
¼ N xBE ij;bμiBE;bσ iBE 2 ; bσiBE ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃbμiBE 1 bμiBEð Þ
nij
s
: ð9Þ
Overall, the log ratio of the probabilities for Mv and M0 is calculated as
described below, and positions with Si > 0 are called as variant candidates.
Si ¼ log
ϕv
Qk
j¼1
N xBE
i
j;bμiBE;bσ iBE 2 
ϕBE
Qk
j¼1
Exp xBE
i
j ; λBE
 
0BBB@
1CCCA: ð10Þ
Performance assessment with replicates. Since no systematic method has been
established to utilize replicates for variant detection, the most straightforward
approaches (intersection, union, and BAM merge) were tested to evaluate the
accuracy thereof. For samples A and B (0.5 and 1% VAFs), intersection and union
sets of MuTect positive calls (calls with KEEP judgment) were tested for their
performances on all platforms. Likewise, merged BAMs of replicates were analyzed
by MuTect, and their positive calls were tested and compared. Conﬂict calls at the
same position were discarded from intersection sets. Performance tests with RePlow
and primitive approaches were achieved in all combinations of library triplicates
(X11X21, X21X31, X11X31, and X11X21X31) for every depth and platform. Average
values with 95% conﬁdence intervals are reported for the results with replicates.
All RePlow results in this article were obtained with the default parameter
settings, regardless of sequencing platform. However, as a result of creating an
excessive number of true mutations in the test-base data sets compared to their size
of target regions, mutation rates were far beyond ordinary values (8.05 × 10−3,
8.60 × 10−3, and 4.83 × 10−3 for ILH, ILA, and ITA, respectively). Due to this
intrinsic bias of mixture data, applying a typical mutation rate (3 × 10−6) to
RePlow severely underestimated the amount of true mutations. Therefore, we used
actual mutation rates for performance tests to avoid such unrealistic distortions.
We also applied actual mutation rates to MuTect for primitive approaches, and
found that it worsened the overall accuracy by generating a larger number of false
positives. We, thus, reported MuTect results with the default parameter settings,
which showed better performances. Despite the underestimation, RePlow still
showed the best overall performance with typical mutation rates, reﬂected in the
extraordinarily low number of false positives (Supplementary Fig. 15).
To test performance in a multi-platform context, only the data sets with the
highest depth of each platform were used (1000× for ILH and 10,000× for ILA and
ITA). Due to differences in the designed targets between sequencing platforms,
only overlapping regions were considered in the evaluation. Target regions and the
answer set of true mutations were adjusted to each platform pair. As a result, 510,
483, and 500 true variants were selected for the answer set of ILHxILA, ILHxITA,
and ILAxITA pairs. The performance of each method was measured for all nine
combinations of library replicates from Xy11Xz11 to Xy31Xz31. Average values with
95% conﬁdence intervals are reported as above.
For independent validation, Tru-Q7 reference standard (1.3% Tier, HD734,
Horizon Dx, Cambridge, UK) was prepared and sequenced by ILH and ITA with
the target coverages of 1000× and 10,000×, respectively. Two commercial cancer
panels (SureSelect custom panel and Ion AmpliSeq cancer hotspot panel v2) that
cover 83 and 50 cancer genes were used to mimic common experimental data. 35
cancer hotspot SNVs covered by both panels were selected as an answer set of true
mutations. Library triplicates were made and sequenced for each platform, and
performance tests were carried out for all combinations of triplicates as stated
above. To verify the performance under the same conditions as in the actual
analysis, a default mutation rate (3 × 10−6) was applied for all methods in the
independent validation. Information for the target regions of cancer panels and
selected hotspot mutations with observed allele frequencies in each replicate are
listed in Supplementary Datas 3 and 4.
Code availability. The implemented program with the source code and a user-
manual is available at https://sourceforge.net/projects/replow/
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The NGS sequencing data of the test-base (36 samples from four spike-in materials and
three matched controls in three sequencing platforms) and of the commercial reference
genomes (six samples including triplicates and two matched controls in two cancer
panels) have been deposited in the NCBI Sequence Read Archive with the accession code
PRJNA517742 [https://www.ncbi.nlm.nih.gov/sra/PRJNA517742]. Deep targeted
sequencing data of intractable epilepsy patients is available upon request to the
corresponding author. The source data underlying Figs. 1b, 2c, 4a, b and Supplementary
Figs. 1–3, 5–8, 10–13, and 15 are provided as a Source Data ﬁle. All other relevant data is
available upon request.
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